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Many orange-coloured fruits contain b-cryptoxanthin in its non-esterified as well as its esterified form. Information concerning the absorp-
tion of b-cryptoxanthin, especially with regard to the metabolism of its fatty acid esters, is rather scarce. The present study assessed the
plasma concentration reached after consumption of a single dose of native b-cryptoxanthin esters from papaya (Carica papaya L.) or non-
esterified b-cryptoxanthin in equal total amounts. In a randomized, single-blind crossover study, twelve subjects were served a portion of
yoghurt containing esterified or non-esterified b-cryptoxanthin (1·3 mg absolute) together with a balanced breakfast. Between the two
intervention days, there was a 2-week depletion period. After a fasting blood sample had been taken, futher samples were taken from
the subjects at 3, 6, 9, 12 and 24 h. The concentration of non-esterified b-cryptoxanthin in the whole plasma was determined by
HPLC; b-cryptoxanthin identification was confirmed by liquid chromatography–atmospheric pressure chemical ionization–MS analyses.
Irrespective of the consumed diet, the plasma b-cryptoxanthin concentrations increased significantly (P¼0·05) and peaked after 6–12 h.
The concentration curves, as well as the areas under the curves, were not distinguishable according to two-sided F and t tests (P¼0·05).
Standardization of b-cryptoxanthin concentrations to plasma triacylglycerol and cholesterol had no impact on the results. Thus, the present
study indicates comparable bioavailability of both non-esterified b-cryptoxanthin and mixtures of b-cryptoxanthin esters. The results
support the existence of an effective enzymatic cleavage system accepting various b-cryptoxanthin esters.
b-Cryptoxanthin: Carotenoid ester: Plasma carotenoid response: Liquid chromatography–atmospheric pressure chemical
ionization–mass spectroscopy
About 600 naturally occurring carotenoids have been iden-
tified. About twenty of these compounds have been
detected in mammal plasma and tissues, with b-carotene,
lycopene, lutein, b-cryptoxanthin and a-carotene account-
ing for .90 % of the circulating carotenoids in human
plasma (Bieri et al. 1985; Rock, 1997). With regard to
provitamin A activity, only a-carotene, b-carotene and
b-cryptoxanthin play an important role in the daily diet.
Noteworthy in this context is b-cryptoxanthin, a xantho-
phyll with only one of its ionone-rings hydroxylated, and
therefore possessing provitamin A activity. Although
b-cryptoxanthin only occurs as a minor carotenoid in the
majority of fruits and vegetables, the concentration of
this micronutrient in the serum can be significantly greater
than that of a-carotene, depending on the diet (Stahl et al.
1992). b-Cryptoxanthin occurs mainly in orange-coloured
fruits such as papaya, orange, apricot, mandarin, peach,
loquat and red pepper. Especially with regard to the
high consumption of oranges and mandarins in some
populations, those fruits are regarded as valuable b-cryp-
toxanthin sources, whereas the consumption of loquat,
peach or apricot with an equally high b-cryptoxanthin
content is seasonally dependent. The occurrence, however,
is not limited only to non-esterified b-cryptoxanthin: a
various number of fatty acid esters are common, mainly
laurate, myristate and palmitate (Wingerath et al. 1995;
Breithaupt & Bamedi, 2001).
Although extensive feeding studies have been conducted
to evaluate absorption, distribution and metabolism of
b-carotene (van Vliet et al. 1995) and lycopene (Ga¨rtner
et al. 1997) in human subjects, little information is avail-
able concerning b-cryptoxanthin, particularly its esters.
While recent studies have dealt with the metabolism of
b-cryptoxanthin in freshwater fish (Goswami, 1984),
others have focused on the metabolism and biological
potency in the rat, with special emphasis on the formation
of retinal (John et al. 1970). Although several studies on
human subjects have quantified b-cryptoxanthin, together
with other fat-soluble micronutrients, in plasma or tissue
(Thurnham, 1988; Ito et al. 1990; Krinsky et al. 1990;
Ross et al. 1995; Olmedilla et al. 1997; Grobusch-Klipstein
et al. 2000), no comparative study concerning the
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absorption efficiency of esterified and non-esterified
b-cryptoxanthin yet exists.
It is generally assumed that carotenoid esters are hydro-
lysed before or during absorption and that the non-esteri-
fied form is absorbed, as in the case of other esterified
isoprenoids (e.g. cholesteryl esters). Wingerath et al.
(1995) investigated the carotenoid pattern in chylomicrons
and serum after ingestion of concentrated tangerine juice
rich in different b-cryptoxanthin esters. They observed
increasing amounts of non-esterified b-cryptoxanthin in
chylomicrons as well as serum, but no b-cryptoxanthin
esters were detectable. This indicates a cleavage in the
intestine before incorporation into lipoproteins. To our
knowledge, up to now no study has compared the plasma
concentrations of b-cryptoxanthin after ingestion of esteri-
fied and non-esterified b-cryptoxanthin using plasma
HPLC analyses. Since non-esterified b-cryptoxanthin is
the only form found in human plasma, it is essential to
include non-esterified b-cryptoxanthin as reference com-
pound in a comparative study.
Since the present study began with a 2-week depletion
phase, the plasma concentration of b-cryptoxanthin was
expected to be significantly reduced. The base concen-
tration of endogenous b-cryptoxanthin was therefore low
enough to allow the use of whole plasma and not of
chylomicrons, as was the case in recent investigations
when studying intestinal absorption of carotenoids (van
Vliet et al. 1995; Wingerath et al. 1995). Since
Wingerath et al. (1995) showed that b-cryptoxanthin
esters appeared neither in plasma nor in chylomicrons,
the whole plasma can be used without investigating the
compartments separately. Consequently, we determined
the plasma concentration curves of b-cryptoxanthin using
the whole plasma after a single oral dose of esterified
or non-esterified b-cryptoxanthin on two occasions,
2 weeks apart.
Since b-cryptoxanthin is yet not available as a food
additive, we used papaya (Carica papaya L.) puree to
obtain native b-cryptoxanthin esters. As well as b-crypto-
xanthin, several minor carotenoids, such as lutein, lyco-
pene and others, occur in this tropical fruit. Although the
b-cryptoxanthin ester pattern of papaya was reported ear-
lier by our group (Breithaupt et al. 2002), the ester compo-
sition of the puree used in the present study was
determined by liquid chromatography (LC)–atmospheric
pressure chemical ionization (APcI)–MS analysis.
Non-esterified b-cryptoxanthin was obtained from the
same plant food source after saponification of the crude
oil extract, with two subsequent clean-up steps. For appli-
cation, both forms were dissolved in sunflower oil and dis-
persed into yoghurt, served together with a balanced
breakfast. Thus, possible effects of the plant food matrix,
which may influence the absorption of carotenoids, can
be excluded. Using similar amounts of total b-cryptox-
anthin in the final diet allowed us to compare directly
the resulting plasma concentrations. The absolute amount
present in both diets was set to 1·3 mg b-cryptoxanthin,
corresponding to a serving size of about 100 g native
papaya, a quantity easily consumable within the conven-
tional daily diet. Thus, a physiological dose of total
b-cryptoxanthin was administered to the subjects.
Materials and methods
Materials
b-Cryptoxanthin as a reference compound was generously
provided by Hoffmann-LaRoche (Basel, Switzerland).
Acetone, 2,6-di-tert-butyl-4-methylphenol, diethyl ether,
ethyl acetate, n-hexane, light petroleum (40–608C),
ethanol and methanol were purchased from Merck
(Darmstadt, Germany). b-apo-120-Carotenal was provided
by BASF (Ludwigshafen, Germany), and methyl-tert-
butyl ether (MTBE) and b-carotene were obtained from
Fluka (Neu-Ulm, Germany). Test kits for in vitro determi-
nation of plasma triacylglycerol (method 334-UV) and
total cholesterol (method 401) were from Sigma (Tauf-
kirchen, Germany). All solvents were of analytical grade
and were distilled before use. For HPLC, ultra-pure water
obtained from a Milli-Q 185 apparatus (Millipore,
Eschborn, Germany) was employed. The papaya puree
was a gift from Schutzgemeinschaft der Fruchtsaft-Indus-
trie e.V. (Nieder-Olm, Germany) and was stored frozen
at 2208C until processing.
Subjects
Twelve human subjects, recruited from staff and students
of the Institute of Food Science (Hannover, Germany),
six female and six male, were divided at random into
two groups of six each. Four of the subjects were smokers.
Three of the female subjects used contraceptives. None of
the subjects suffered from gastrointestinal diseases, or took
laxatives or drugs lowering plasma triacylglycerol or
cholesterol concentrations. They did not take any sup-
plements containing carotenoids or vitamins in the 8
weeks before and during the study. Subjects were
requested to keep to a normal diet, but to avoid b-cryptox-
anthin-rich fruit such as peaches, oranges, papaya, apricots
and red peppers for the 2 weeks before and the 2 weeks
during the intervention period. Products manufactured
from these plant sources (e.g. orange juice, dried apricots,
vitamin-fortified mixed fruit beverages) were also to be
avoided. The study protocol was approved by the Medical
Ethics Committee of the Medizinische Hochschule,
Hannover, and the participants provided written informed
consent.
Study design
The study was designed as a single-blind crossover study
for 16 d and consisted of two experimental days, separated
by a 2-week depletion period, during which no supplemen-
tation was carried out. On each of the 2 d, subjects received
a balanced breakfast with the respective supplementation
(see Table 1). For the two experimental days, subjects
were instructed not to consume any fruits or products
made from fruits, including juices. Carotenoid supplemen-
tation was performed by mixing a serving of 150 g com-
mercial whole-milk yoghurt (35 g fat/kg) with 4 g spiked
sunflower oil, resulting in a total of 1·3 mg b-cryptoxanthin
in either the esterified or non-esterified form. The yoghurt
was consumed together with a standardized breakfast,
with a total of approximately 24 g fat and 2100 kJ
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(about 500 kcal; see Table 2). Blood samples were
collected before (0 h) and after supplementation (3, 6, 9,
12 and 24 h). After 24 h, participants were again instructed
to consume a low b-cryptoxanthin diet for another 2 weeks
to allow for depletion. After 2 weeks, the crossover was
performed.
Preparation of supplements
Extraction of carotenoids. Carotenoids were extracted
from papaya puree using a ternary solvent mixture of
light petroleum (40–608C)–ethyl acetate–methanol
(1:1:1, by vol.). A sample of the puree (500 g) was trans-
ferred into a 2 litre flask and extracted with 500 ml solvent
by mixing thoroughly. The extract was separated from the
plant tissue employing a Bu¨chner funnel. To allow for
complete extraction, portions of 200 ml solvent were
poured on to the filter cake and sucked off. This step
was repeated until the filter cake was nearly colourless.
The resulting extract was transferred into a separating
funnel and washed with water containing a saturated
solution of NaCl to allow for a good phase separation.
The water layer was discarded, while the organic layer
was transferred into an Erlenmeyer flask, dried with
anhydrous sodium sulfate, filtered, and evaporated to dry-
ness. The resulting oily, orange residue was redissolved
in light petroleum (40–608C) and stored at 2208C.
Isolation of non-esterified b-cryptoxanthin. To obtain
non-esterified b-cryptoxanthin, the crude oil was saponi-
fied using methanolic KOH (300 g/l methanol). Therefore,
the solution obtained as described earlier was evaporated to
dryness and the remaining oil dissolved in 100 ml diethyl
ether. After the addition of methanolic KOH (5 ml), the
mixture was kept at room temperature for 12 h, protected
from light. The diethyl ether phase was washed
twice with water, dried with sodium sulfate and filtered.
To separate all-trans-b-cryptoxanthin from cis-isomers,
semi-preparative HPLC was employed using an isocratic sol-
vent system (methanol–MTBE (57:43, v/v); retention time
of the all-trans-isomer 5·5 min). Instantly after isolation, the
combined eluates from multiple separations were evaporated
under reduced pressure and dim light. For storage, the now
crystalline b-cryptoxanthin was redissolved in light pet-
roleum (40–608C) and was frozen at 2208C in a N2-filled
flask. For supplementation, light petroleum (40–608C) was
removed and b-cryptoxanthin was dissolved in sunflower
oil. The concentration of the xanthophyll was adjusted to
321 (SD10) mg/g (n 3) by dilution with oil. Using 4 g oil per
diet, this corresponds to an intake of 1·3 mg non-esterified
b-cryptoxanthin (see p. 796).
Clean-up of native b-cryptoxanthin esters. For clean-
up, a chromatographic glass column (300 £ 20 mm) was
packed with silica gel 60 (0·063–0·200 mm), suspended
in light petroleum (40–608C), to approximately 100 mm
height. The light petroleum solution resulting from a
work-up of 500 g papaya puree was poured carefully onto
the column, allowing the solvent and apolar compounds
to run through. To elute carotenoids, mixtures of acetone
in light petroleum were used. At 20 ml acetone/l, lycopene
and the major portion of b-carotene were eluted from the
column, together with other lipid constituents; b-crypto-
xanthin esters were obtained with 20–40 ml acetone/l.
More polar carotenoids (e.g. non-esterified b-cryptoxanthin
and lutein) remained on the column and were discarded.
Fractions containing b-cryptoxanthin esters were evapor-
ated to dryness and redissolved in light petroleum. For sup-
plementation, the solvent was removed and b-cryptoxanthin
esters were dissolved in sunflower oil. The concentration
of xanthophyll was set to 319 (SD 19) mg/g oil (n 3;
determined after saponification) by dilution with oil.
Using 4 g oil per diet, this results in an intake of 1·3 mg
b-cryptoxanthin in esterified form. For LC–APcI–MS
analyses of native b-cryptoxanthin esters, the residue of
one additional preparation was dissolved in methanol–
MTBE (1:1, v/v). The stability of the respective caroten-
oids in sunflower oil and in the yoghurt was tested at the
end of the study. After 2 weeks storage at 2208C, both
spiked oils showed neither degradation nor isomerization
(,1 % compared with the initial content); likewise,
carotenoid esters were stable in the yoghurt.
Plasma sample preparation. At any blood withdrawal,
about 5 ml was sampled from each participant. Immedi-
ately after collection, the plasma was separated from the
erythrocytes by centrifugation (5000 rpm, 10 min) and
stored at 2208C in plastic caps. The work-up procedure
is based on a method described by Khachik et al. (1997).
In brief, a sample of the plasma (0·75–1·00 ml) was
precipitated with ethanol (1 ml, containing 10 g butylated
hydroxytoluene/l) and mixed vigorously on a shaker
(Vortex Genie 2; Scientific Industries, Bohemia, NY,
USA). A portion (1 ml) of the internal standard (2mg
b-apo-120-carotenal/l ethanol) was added and the solution
mixed again. To extract the carotenoids, 2 ml n-hexane
were added to the homogenate, the mixture stirred once
again and the precipitate spun down in a Biofuge R
centrifuge (Heraeus, Hanau, Germany) at 644 g at 108C
for 5 min. The organic layer was transferred into a 10 ml
brown glass vial and the extraction procedure was
Table 1. Design of the single-blind crossover study*
Group Day 1 Day 2
Group 1 (n 6) b-Cryptoxanthin ester Non-esterified
b cryptoxanthin
Group 2 (n 6) Non-esterified
b cryptoxanthin
b-Cryptoxanthin ester
* Subjects were divided at random into two groups; the intervention was
carried out on two days 2 weeks apart.
Table 2. Composition of the standardized breakfast*
Quantity (g) Fat (g) Energy (kJ)
Bread roll 40·0 0·7 462
Wholegrain bread 30·0 0·3 245
Butter 10·0 8·3 309
Cream cheese 320 g fat/kg 16·7 5·3 235
Full-fat yoghurt 35 g fat/kg 150·0 5·3 440
Oil suspension 4·0 4·0 148
Honey 20·0 2 257
Total 23·9 2096
* Values were calculated from food composition tables (Scherz et al. 2000).
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repeated. The combined organic phases were evaporated
and redissolved in 1 ml methanol–MTBE (1:1, v/v). The
solution obtained was passed through a 0·45mm membrane
filter and was used immediately for HPLC analysis. All
steps were performed under dim light. To determine poss-
ible losses during the work-up procedure, the HPLC peak
areas of the internal standard, b-apo-120-carotenal, were
monitored. The recovery of b-apo-120-carotenal from
extractions of various samples accounted for .95 %.
Plasma triacylglycerol and total cholesterol were measured
manually by using commercial in vitro enzymatic test kits
(methods 334-UV and 401; Sigma).
Analysis and chromatography. Carotenoids were quan-
tified by HPLC on a Hewlett Packard HPLC (model 1100;
Waldbronn, Germany) as described by Breithaupt (2000),
using a variable wavelength detector set to 450 nm and
two mobile phases for carotenoid separation (methanol–
MTBE–water (81:15:4, by vol. (A); 6:90:4, by vol. (B)).
The gradient was slightly modified to (time (min), % A):
0, 99; 39, 44; 45, 0; 50, 99; 55, 99. The system for semi-
preparative HPLC was itemized by Breithaupt & Bamedi
(2001). LC–APcI–MS was run on a Micromass (Manche-
ster, UK) VG platform II quadrupole MS equipped with an
APcI interface, operating in the positive mode, as
described by Breithaupt & Schwack (2000). Within a run-
ning time of 55 min, all major carotenoids (lutein, zea-
xanthin, b-cryptoxanthin, a-carotene, b-carotene,
lycopene) and the internal standard (b-apo-120-carotenal)
were baseline separated. The chromatogram matched the
normal carotenoid distribution as described in the literature
(Rock, 1997; Bo¨hm & Bitsch, 1999). To verify b-crypto-
xanthin identification in human plasma, six plasma samples
from group 1 (day 1) were pooled, cleaned up through a
small glass column (150 £ 10 mm) packed with silica
gel (according to the procedure described for b-crypto-
xanthin ester isolation), the eluate concentrated to 200ml
and analysed with LC–APcI–MS.
Statistics
Results are expressed as mean values and standard
deviations. The areas under the curve (AUC (0–24 h))
were determined automatically by the trapezoidal rule
after subtraction of the fasting plasma b-cryptoxanthin
concentrations. Likewise, plasma concentrations were
corrected by the individual fasting b-cryptoxanthin
concentrations. For comparison of the plasma concen-
trations and the AUC of the two groups and days, two-sided
F test and t test were employed (each P¼0·05). All statistics
were performed with Microsoft Excel 2000, Microsoft
Corporation, Redmond, USA.
Results
All participants were instructed to consume a low-caroten-
oid diet for 2 weeks before and during the study in order to
avoid falsification. Hence, fasting base concentrations of
b-cryptoxanthin were only 0·06 (SD 0·05) (range 0·0–0·2)
mmol/l (n 12). Further characteristics of the participants
(fasting plasma concentrations of cholesterol and triacyl-
glycerol) on both intervention days are shown in Table 3.
Fig. 1 shows two HPLC chromatograms illustrating the
constitution of both supplements used on both days: chro-
matogram A shows the native carotenoid ester pattern of
the purified papaya extract. Peak assignment was carried
out by LC–APcI–MS analyses in the positive mode
by evaluation of the respective quasimolecular ions
([M þ H]þ), fragment ions and the absorption spectra.
Besides b-cryptoxanthin caprate (peak 3), laurate (peak
4), myristate (peak 5) and palmitate (peak 6), a small
amount of b-carotene (peak 2) was present, whereas non-
esterified b-cryptoxanthin (peak 1) was totally absent.
Efforts to reduce the b-carotene concentration by optimiz-
ation of the open-column chromatography were not suc-
cessful; the same is true for a minute amount of lycopene
(peak 7). Since the concentrations of b-carotene and
lycopene were comparatively low, both probably did not
compete with excess b-cryptoxanthin and thus should not
have affected absorption kinetics. Several minor peaks
represented native cis-isomers of b-cryptoxanthin esters
and were not studied in detail. Chromatogram B is of a
saponified sample obtained after further purification by
semi-preparative HPLC. In this supplement, only non-
esterified b-cryptoxanthin (peak 1) was present.
Plasma carotenoids were determined using an HPLC
system (450 nm) equipped with a C30 reversed-phase
Fig. 1. Typical HPLC chromatograms (450 nm) of native papaya
(Carica papaya L.) after clean-up by column chromatogaphy on
silica gel (A) and of a saponified sample (B). AU, absorbance units.
Peak assignment was done by analyses with liquid chromatog-
raphy–atmospheric pressure chemical ionization–MS as follows:
peak 1, non-esterified all-trans-b-cryptoxanthin; peak 2, b-carotene;
peak 3, b-cryptoxanthin caprate; peak 4, b-cryptoxanthin laurate;
peak 5, b-cryptoxanthin myristate; peak 6, b-cryptoxanthin palmi-
tate; peak 7, lycopene. For details of procedures, see p. 797.
Table 3. Characteristics of the subjects
(Mean values and standard deviations)
Day 1 Day 2
Mean SD Mean SD
Age (years)* 27·3 5·7
BMI (kg/m2)† 24·5 3·0
Fasting plasma concentrations†
Total cholesterol (mmol/l) 4·73 0·92 4·93 0·95
Triacylglycerol (mmol/l) 1·09 0·58 1·18 0·59
b-Cryptoxanthin (mmol/l) 0·06 0·05 0·05 0·04
* n 12 (six male and six female).
† n 12 (days 1 and 2 separately).
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column. Confirmation of carotenoids in human plasma by
LC–MS has been described earlier by Khachik et al.
(1992), who used a nitrile-bonded column for separation.
b-Cryptoxanthin was unequivocally identified by its u.v.-
visible spectrum (420–452–478 nm; diode array detector)
and its quasimolecular ion m/z 553 [M þ H]þ in a
pooled sample. Typical examples of HPLC chromatograms
(extended sections) obtained from the plasma of one indi-
vidual (group 1, day 1) before and after ingestion of ester-
ified b-cryptoxanthin are presented in Fig. 2. However,
neither HPLC nor LC–APcI–MS analyses gave evidence
for the presence of b-cryptoxanthin esters in plasma.
Minor peaks in the time window indicated were also pre-
sent in fasting plasma samples and could not be unequivo-
cally allocated to b-cryptoxanthin esters. The absence of
b-cryptoxanthin esters is in accordance with the results
of Wingerath et al. (1995), who also were not able to
detect these compounds either in serum or in chylomicrons.
For quantitative assessment, the average concentrations
of b-cryptoxanthin v. the time of sampling were plotted
(Fig. 3). Independently of spiking the diets with esterified
or non-esterified b-cryptoxanthin, the plasma concentration
of all participants increased significantly (P,0·05)
after consumption of b-cryptoxanthin-enriched yoghurts.
Concentration curves were statistically not distinguishable
according to two-sided F test and t test (P,0·05) applied
to both groups. The absorption maxima in the plasma
were reached between 6 and 12 h after supplementation
at both intervention days. The maximum plasma value
measured in an individual in the study was 205 nmol
(113mg)/l; this value occurred after supplementation with
esterified b-cryptoxanthin.
In order to account for potential variations in the blood
total triacylglycerol or cholesterol levels, all b-crypto-
xanthin concentrations were corrected for both triacylgly-
cerol and cholesterol. Each b-cryptoxanthin value was
divided by the corresponding triacylglycerol (or choles-
terol) concentration and multiplied by the mean triacylgly-
cerol (or cholesterol) concentration of all participants.
As an example, b-cryptoxanthin plasma responses adjusted
for triacylglycerol are shown in Fig. 4. Standardization for
total cholesterol (results not shown) revealed the same
results.
To compare the absorption behaviour for esterified
and non-esterified b-cryptoxanthin, a summarized value
comprising all sampled points, not only the maxima, is
required. This problem can be solved by evaluation of
the AUC, calculated from the appropriate figure (plasma
concentration of b-cryptoxanthin v. time of sampling). Fur-
thermore, the AUC is proportional to the bioavailability
(Yao et al. 2000), hence allowing an estimation of how
well either of the two forms are resorbed. Mean AUC
and standard deviations were calculated for days 1 and 2
and groups 1 and 2. This proved AUC of the groups not
to be distinguishable, either within one group, or between
the two groups (two-sided F test and t test, P¼0·05).
Therefore, AUC were combined for days 1 and 2, summing
up total participants according to the b-cryptoxanthin
forms ingested. This resulted in mean AUC of: esterified
b-cryptoxanthin 0·91 (SD 0·98) mmol/h per litre (n 12);
non-esterified b-cryptoxanthin 1·09 (SD 0·82) mmol/h per
litre (n 12). This demonstrates again that AUC were not
distinguishable. Thus, plasma concentrations of b-cryptox-
anthin were comparable, even with regard to AUC,
Fig. 2. Typical HPLC chromatograms (extended sections; 450 nm)
of plasma samples (group 1, day 1) obtained from one subject 0 (A)
and 24 (B) h after consumption of esterified b-cryptoxanthin. Peak
assignment: peak 1, non-esterified all-trans-b-cryptoxanthin; peak
2, b-carotene; peak 7, lycopene. AU, absorbance units; , , reten-
tion time window in which b-cryptoxanthin esters appear. For details
of subjects and procedures, see Table 3 and p. 797.
Fig. 3. Dependence of plasma b-cryptoxanthin concentrations on sampling time after a single dose of esterified b-cryptoxanthin (O) or non-
esterified b-cryptoxanthin (A; 1·3 mg each). (A), day 1; (B), day 2. Values are means with standard deviations shown by vertical bars (twelve
per group). For details of subjects and procedures, see Table 3 and p. 797.
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whether the subjects were given esterified or non-esterified
b-cryptoxanthin.
Discussion
Although it is presumed that dietary b-cryptoxanthin
esters are hydrolysed in the intestine before absorption,
results are not yet available comparing the plasma
concentrations achieved after ingestion of esterified or
non-esterified forms. Consequently, a crossover study was
designed using esterified or non-esterified b-cryptoxanthin
from a natural source, applied as one single dose together
with a balanced breakfast. Fasting base concentrations of
b-cryptoxanthin given in the literature usually range
between 0·2 and 0·5mmol/l (0·21mmol/l, Krinsky et al.
1990; 0·48mmol/l, Grobusch-Klipstein et al. 2000). In
a recent publication, b-cryptoxanthin levels in fasting
sera of subjects from five European countries ranged
from 0·14 (Northern Ireland, UK) to 0·40mmol/l (Spain)
(Olmedilla et al. 2001). Thus, the fasting base concen-
trations of b-cryptoxanthin were well below the usually
observed concentration in human plasma, and demon-
strated the effect of the depletion phase before beginning
the intervention. Both triacylglycerol and total cholesterol
concentrations were in the normal range for all subjects
in both groups (desirable concentrations: triacylglycerol
,1·25 mmol/l, cholesterol ,5·18 mmol/l; Jordan et al.
1995).
After ingestion of b-cryptoxanthin-rich diets, absorption
maxima in the plasma were reached between 6 and 12 h
after application. This is in accordance with the obser-
vations of Wingerath et al. (1995), who found serum
b-cryptoxanthin concentrations increasing up to 9 h after
ingestion of tangerine juice concentrate. The maxima prob-
ably represent a transient increase in chylomicron-associ-
ated b-cryptoxanthin. A second peak, usually observed in
plasma b-carotene studies after 24–48 h and representing
the increase in the LDL fraction (Rock, 1997), was not
observed during the study period of 24 h. Thus, each of
the curves showed only one maximum. Since concentration
curves were statistically not distinguishable, bioavailability
of both non-esterified b-cryptoxanthin and a native mixture
of different b-cryptoxanthin esters were comparable in our
present study.
The maximum plasma b-cryptoxanthin concentration
obtained was 205 nmol (113mg)/l). Based on the assump-
tion that about 4 % of the body weight is plasma (2·4
litres plasma/60 kg; Barua, 1999), this concentration corre-
sponds to an absolute amount of 271mg b-cryptoxanthin,
amounting to approximately one-quarter of the applied
dose. This is in accordance with a relatively low efficiency
of carotenoid absorption, reported to range from 5 % for
raw vegetables up to 50 % or more for micellar solutions
(Olson, 1994). Most of the carotenoid might have been
metabolized to vitamin A (which was not studied here)
or excreted through the gastrointestinal tract. However, a
significant increase in b-cryptoxanthin plasma concen-
trations was observed for all participants. After consuming
esterified b-cryptoxanthin, a higher variability in plasma
responses was observed (Fig. 3). Although the definite
reason for this effect is unknown, a possible explanation
could be different enzyme activity of individual partici-
pants. Remarkably, the mean plasma b-cryptoxanthin
concentrations on the second day seemed to show a
lower increase (Fig. 3). Applying statistical methods
(two-sided F test and t test, P¼0·05) proved both data
sets not to be distinguishable, showing that there is in
fact no difference in the absorption characteristics of
both days. Yet we are of the opinion that the statistical
result is not to be overestimated, since the deviation of
the plasma concentrations of the participants is relatively
high. Upon this fact, the base concentrations of days 1
and 2 were compared and were found to be similar; thus,
a lessened uptake due to plasma ‘saturation’ is not very
likely. It can be assumed that the time frame of 2 weeks
between the two experimental days was not sufficient to
ensure the same metabolic state as at the beginning of
the study. The reason for this behaviour is as yet unknown
and requires further investigation.
Carotenoids are transported in association with lipopro-
teins, so plasma triacylglycerol and cholesterol concen-
trations are usually correlated with circulating carotenoid
concentrations (Thurnham, 1989). As plasma triacylgly-
cerol depends on the diet consumed on the intervention
day, which was not controlled by the present study, a
Fig. 4. Plasma b-cryptoxanthin concentrations, standardized to the plasma triaclyglycerol concentration, after a single dose of esterified
b-cryptoxanthin (O) or non-esterified b-cryptoxanthin (A; 1·3 mg each). (A), day 1; (B), day 2. Values are means with standard deviations
shown by vertical bars (twelve per group). For details of subjects and procedures, see Table 3 and p. 797.
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high additional fat intake may result in a lowered plasma
carotenoid response. Thus, plasma b-cryptoxanthin con-
centrations were corrected for both total triacylglycerol
and cholesterol (Fig. 4). The shape of the resulting
curves is close to that of the unadjusted data set, pointing
out that standardization did not change the overall results
when performed. One exception is the standard deviation
corresponding to values obtained 6 h after the intervention.
This is due to high individual deviations in the triacylgly-
cerol deviation of one single person. Further on, standard-
ization to triacylglycerol demonstrates that the plasma
b-cryptoxanthin response is not influenced by triacylgly-
cerol consumed by the participants during the intervention
days.
Quantitatively, there was no difference in the resulting
plasma response when the subjects were given esterified
or non-esterified b-cryptoxanthin. Since b-cryptoxanthin
was administered in its esterified or non-esterified form,
resulting in comparable plasma concentrations, it may be
concluded that there is no preferential uptake of the
non-esterified form, as discussed by Wingerath et al.
(1995). In fact, the present results support the existence
of an effective enzymatic cleavage system in the gut
lumen, accepting different natural b-cryptoxanthin esters
as substrates.
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